Oct 14 2011 | News
Teva announced that it has now received all regulatory approvals required to complete its planned purchase of Cephalon after the European Commission cleared the transaction.
|
Jun 14 2011 | News
Teva Pharmaceutical Industries Ltd. and Cephalon, Inc.
announced today that, as expected, each party has received a request for
additional information (commonly referred to as a "second request")
from the U.S. Federal Trade Commission (FTC) in connection with Teva's pending
acquisition of Cephalon.
|
May 2 2011 | News
NEW YORK
(AP) — Teva Pharmaceutical Industries Ltd. has agreed to buy Cephalon Inc. for
$6.8 billion in a deal that would give the world's largest generic drug
developer a range of biotechnology drugs aimed at cancer and other conditions
|
Apr 13 2011 | News
Cephalon, Inc. has announced that its wholly-owned
subsidiary, Cephalon CXS Holdings Pty Ltd (Cephalon), has lodged the offer document
(Bidder's Statement) for its A$0.70 a share offer for ChemGenex Pharmaceuticals
Limited (ASX: CXS) (ChemGenex) with the Australian Securities and Investments
Commission.
|
Apr 6 2011 | News
Cephalon Inc.'s shares fell slightly in pre-market trading a
day after the U.S. drug
company formally rejected a hostile takeover bid by Canada's Valeant Pharmaceuticals
International.
|
Mar 25 2011 | News
Cephalon, Inc. announced that today the United States
District Court in Delaware
upheld the validity of Cephalon's U.S. Patent Number 6,264,981 patent and found
that Watson Pharmaceuticals, Inc.'s proposed generic version of FENTORA®
(fentanyl buccal tablet) infringes that patent.
|
Mar 22 2011 | News
Cephalon, Inc. has signed a definitive merger agreement
under which it will acquire all of the outstanding capital stock of Gemin X
Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing
first-in-class cancer therapeutics, for $225 million cash on a cash-free,
debt-free basis.
|
Mar 14 2011 | News
NEW YORK (AP) — A federal court overturned two of the
patents on Cephalon Inc.'s painkiller Fentora, according to Cephalon and Watson
Pharmaceuticals Inc., which is challenging the patents.
|
Feb 10 2011 | News
Cephalon, Inc. and Alba Therapeutics Corporation, a privately held
biopharmaceutical company, today announced that the companies have signed an
agreement providing Cephalon with an option to purchase all of Alba's assets
relating to larazotide acetate, a tight junction modulator, progressing toward
a Phase IIb clinical trial for the treatment of celiac disease.
|
Dec 23 2010 | News
Cephalon, Inc. announced today that its Board of Directors
has appointed J. Kevin Buchi as Chief Executive Officer and a member of the
company's Board. The Board will address the role of company Chairman in the
future. William P. Egan will continue to serve as Cephalon's independent
Presiding Director.
|